<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01936844</url>
  </required_header>
  <id_info>
    <org_study_id>VCU HM15347</org_study_id>
    <nct_id>NCT01936844</nct_id>
  </id_info>
  <brief_title>Interleukin (IL)-1 Blockade in Acute Heart Failure (Anakinra ADHF)</brief_title>
  <official_title>Interleukin-1 Blockade in Acute Decompensated Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anakinra ADHF is a double-blind randomized clinical trial of anakinra, recombinant human
      interleukin-1 receptor blocker, or placebo in patients with acute decompensated heart failure
      with the aim to quench the acute inflammatory response, as measured by the
      area-under-the-curve for C reactive protein over 14 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>C Reactive Protein</measure>
    <time_frame>3 days</time_frame>
    <description>The proportional area-under-the-curve for plasma C reactive protein (CRP) levels measured during the first 3 days of admission. The proportion (y-axis) is calculated at each time-point with respect to the baseline CRP. The resultant y-axis is a unitless proportion. The x-axis is listed as &quot;days&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Ejection Fraction</measure>
    <time_frame>14 days</time_frame>
    <description>Change in left ventricular ejection fraction (LVEF) between admission and 14 day follow up. This value is expressed as absolute change in measured LVEF. For example, if baseline LVEF = 20% and 14 day LVEF = 25%, this would be reported as an absolute change of 5%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brachial Artery Vasoreactivity</measure>
    <time_frame>14 days</time_frame>
    <description>Change in flow mediated vasodilatation (FMD) of the brachial artery. Brachial artery FMD is calculated as the percentage increase in brachial artery diameter with hyperemia (an increase in the quantity of blood flow to a body part) induced relative to the resting brachial artery diameter. Percentage of brachial artery diameter is measured as FMD diameter/basal diameter. The change is FMD is reported as the % change in FMD from baseline to 14 days.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Anakinra (short)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anakinra 100 mg twice daily for the first 3 days followed by 100 mg daily for days 4-14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo injections twice daily for the first 3 days then once daily for days 4-14.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anakinra (high dose)</intervention_name>
    <description>Anakinra 100 mg daily twice daily for days 1, 2, and 3</description>
    <arm_group_label>Anakinra (short)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anakinra (standard dose)</intervention_name>
    <description>Anakinra 100 mg daily for days 4-14</description>
    <arm_group_label>Anakinra (short)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo twice daily for days 1, 2, and 3</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo daily for days 4-14</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All 5 criteria need to be met for enrollment of the patient in the study

          1. Primary diagnosis of acute decompensated heart failure within the last 24 hours as
             evidenced by both of the following:

               1. dyspnea or respiratory distress or tachypnea at rest or with minimal exertion

               2. evidence of elevated cardiac filling pressure or pulmonary congestion (at least
                  one of the conditions must be met);

             i. pulmonary congestion/edema at physical exam OR chest x-ray; ii. plasma Brain
             Natriuretic Peptide (BNP) levels ≥200 pg/mL; iii.invasive measurement of left
             ventricular end-diastolic pressure &gt;18 mmHg or of pulmonary artery occluding pressure
             (wedge) &gt;16 mmHg.

          2. Left ventricular systolic dysfunction (LVEF&lt;40%) during index hospitalization or prior
             12 months.

          3. Age ≥18 years old

          4. Willing and able to provide written informed consent.

          5. Screening plasma C-reactive protein levels &gt;5 mg/L.

        Exclusion Criteria Subjects will not be eligible if they meet any of the following 15
        exclusion criteria.

          1. The primary diagnosis for admission is NOT decompensated heart failure, including
             diagnosis of acute coronary syndromes, hypertensive urgency/emergency, tachy- or
             brady-arrhythmias.

          2. Concomitant clinically significant comorbidities that would interfere with the
             execution or interpretation of the study including but not limited to acute coronary
             syndromes, uncontrolled hypertension or orthostatic hypotension, tachy- or
             brady-arrhythmias, acute or chronic pulmonary disease or neuromuscular disorders
             affecting respiration.

          3. Recent (previous 3 months) or planned cardiac resynchronization therapy (CRT),
             coronary artery revascularization procedures, or heart valve surgeries.

          4. Previous or planned implantation of left ventricular assist devices or
             heart-transplant.

          5. Chronic use of intravenous inotropes.

          6. Recent (&lt;14 days) use of immunosuppressive or anti-inflammatory drugs (not including
             Non-Steroidal Anti-Inflammatory Drugs [NSAIDs]).

          7. Chronic inflammatory disorder (including but not limited to rheumatoid arthritis,
             systemic lupus erythematosus).

          8. Active infection (of any type);

          9. Chronic/recurrent infectious disease (including Hepatitis B virus [HBV], Hepatitis C
             virus [HCV], and HIV/AIDS).

         10. Prior (within the past 10 years) or current malignancy.

         11. Any comorbidity limiting survival or ability to complete the study.

         12. End stage kidney disease requiring renal replacement therapy.

         13. Neutropenia (&lt;2,000/mm3) or Thrombocytopenia (&lt;50,000/mm3).

         14. Pregnancy.

         15. Angina, arrhythmias, or electrocardiograph (ECG) changes that limit maximum exertion
             during cardiopulmonary exercise testing obtained during the baseline testing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin W Van Tassell, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2013</study_first_submitted>
  <study_first_submitted_qc>September 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2013</study_first_posted>
  <results_first_submitted>January 15, 2016</results_first_submitted>
  <results_first_submitted_qc>February 19, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 22, 2016</results_first_posted>
  <last_update_submitted>March 31, 2016</last_update_submitted>
  <last_update_submitted_qc>March 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data may be available upon request</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Anakinra (Short)</title>
          <description>Anakinra 100 mg twice daily for the first 3 days followed by 100 mg daily for days 4-14
Anakinra (high dose): Anakinra 100 mg daily twice daily for days 1, 2, and 3
Anakinra (standard dose): Anakinra 100 mg daily for days 4-14</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo injections twice daily for the first 3 days then once daily for days 4-14.
Placebo: Placebo twice daily for days 1, 2, and 3
Placebo: Placebo daily for days 4-14</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Anakinra (Short)</title>
          <description>Anakinra 100 mg twice daily for the first 3 days followed by 100 mg daily for days 4-14
Anakinra (high dose): Anakinra 100 mg daily twice daily for days 1, 2, and 3
Anakinra (standard dose): Anakinra 100 mg daily for days 4-14</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo injections twice daily for the first 3 days then once daily for days 4-14.
Placebo: Placebo twice daily for days 1, 2, and 3
Placebo: Placebo daily for days 4-14</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="49" upper_limit="64"/>
                    <measurement group_id="B2" value="54" lower_limit="49" upper_limit="66"/>
                    <measurement group_id="B3" value="58" lower_limit="49" upper_limit="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>C-reactive protein</title>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.3" lower_limit="10.8" upper_limit="95.9"/>
                    <measurement group_id="B2" value="27.4" lower_limit="12.0" upper_limit="47.2"/>
                    <measurement group_id="B3" value="23.8" lower_limit="10.9" upper_limit="46.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>C Reactive Protein</title>
        <description>The proportional area-under-the-curve for plasma C reactive protein (CRP) levels measured during the first 3 days of admission. The proportion (y-axis) is calculated at each time-point with respect to the baseline CRP. The resultant y-axis is a unitless proportion. The x-axis is listed as &quot;days&quot;</description>
        <time_frame>3 days</time_frame>
        <population>1 patient in each group withdrew from the study prior to collection of data for the primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Anakinra (Short)</title>
            <description>Anakinra 100 mg twice daily for the first 3 days followed by 100 mg daily for days 4-14
Anakinra (high dose): Anakinra 100 mg daily twice daily for days 1, 2, and 3
Anakinra (standard dose): Anakinra 100 mg daily for days 4-14</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo injections twice daily for the first 3 days then once daily for days 4-14.
Placebo: Placebo twice daily for days 1, 2, and 3
Placebo: Placebo daily for days 4-14</description>
          </group>
        </group_list>
        <measure>
          <title>C Reactive Protein</title>
          <description>The proportional area-under-the-curve for plasma C reactive protein (CRP) levels measured during the first 3 days of admission. The proportion (y-axis) is calculated at each time-point with respect to the baseline CRP. The resultant y-axis is a unitless proportion. The x-axis is listed as &quot;days&quot;</description>
          <population>1 patient in each group withdrew from the study prior to collection of data for the primary endpoint.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.09" lower_limit="1.73" upper_limit="2.61"/>
                    <measurement group_id="O2" value="2.93" lower_limit="2.36" upper_limit="3.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Ejection Fraction</title>
        <description>Change in left ventricular ejection fraction (LVEF) between admission and 14 day follow up. This value is expressed as absolute change in measured LVEF. For example, if baseline LVEF = 20% and 14 day LVEF = 25%, this would be reported as an absolute change of 5%.</description>
        <time_frame>14 days</time_frame>
        <population>Some patients did not undergo LVEF assessment at 14 days because they did not show up to their scheduled appointment.</population>
        <group_list>
          <group group_id="O1">
            <title>Anakinra (Short)</title>
            <description>Anakinra 100 mg twice daily for the first 3 days followed by 100 mg daily for days 4-14
Anakinra (high dose): Anakinra 100 mg daily twice daily for days 1, 2, and 3
Anakinra (standard dose): Anakinra 100 mg daily for days 4-14</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo injections twice daily for the first 3 days then once daily for days 4-14.
Placebo: Placebo twice daily for days 1, 2, and 3
Placebo: Placebo daily for days 4-14</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Ejection Fraction</title>
          <description>Change in left ventricular ejection fraction (LVEF) between admission and 14 day follow up. This value is expressed as absolute change in measured LVEF. For example, if baseline LVEF = 20% and 14 day LVEF = 25%, this would be reported as an absolute change of 5%.</description>
          <population>Some patients did not undergo LVEF assessment at 14 days because they did not show up to their scheduled appointment.</population>
          <units>percent LVEF</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="3" upper_limit="14"/>
                    <measurement group_id="O2" value="0" lower_limit="-16" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brachial Artery Vasoreactivity</title>
        <description>Change in flow mediated vasodilatation (FMD) of the brachial artery. Brachial artery FMD is calculated as the percentage increase in brachial artery diameter with hyperemia (an increase in the quantity of blood flow to a body part) induced relative to the resting brachial artery diameter. Percentage of brachial artery diameter is measured as FMD diameter/basal diameter. The change is FMD is reported as the % change in FMD from baseline to 14 days.</description>
        <time_frame>14 days</time_frame>
        <population>Some patients did not undergo assessment at 14 days because they did not show up to their scheduled appointment.</population>
        <group_list>
          <group group_id="O1">
            <title>Anakinra (Short)</title>
            <description>Anakinra 100 mg twice daily for the first 3 days followed by 100 mg daily for days 4-14
Anakinra (high dose): Anakinra 100 mg daily twice daily for days 1, 2, and 3
Anakinra (standard dose): Anakinra 100 mg daily for days 4-14</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo injections twice daily for the first 3 days then once daily for days 4-14.
Placebo: Placebo twice daily for days 1, 2, and 3
Placebo: Placebo daily for days 4-14</description>
          </group>
        </group_list>
        <measure>
          <title>Brachial Artery Vasoreactivity</title>
          <description>Change in flow mediated vasodilatation (FMD) of the brachial artery. Brachial artery FMD is calculated as the percentage increase in brachial artery diameter with hyperemia (an increase in the quantity of blood flow to a body part) induced relative to the resting brachial artery diameter. Percentage of brachial artery diameter is measured as FMD diameter/basal diameter. The change is FMD is reported as the % change in FMD from baseline to 14 days.</description>
          <population>Some patients did not undergo assessment at 14 days because they did not show up to their scheduled appointment.</population>
          <units>percentage change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7" lower_limit="-44.5" upper_limit="98.2"/>
                    <measurement group_id="O2" value="-45.2" lower_limit="-101.0" upper_limit="45.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Anakinra (Short)</title>
          <description>Anakinra 100 mg twice daily for the first 3 days followed by 100 mg daily for days 4-14
Anakinra (high dose): Anakinra 100 mg daily twice daily for days 1, 2, and 3
Anakinra (standard dose): Anakinra 100 mg daily for days 4-14</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo injections twice daily for the first 3 days then once daily for days 4-14.
Placebo: Placebo twice daily for days 1, 2, and 3
Placebo: Placebo daily for days 4-14</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening heart failure or Readmission for heart failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Serious infection/sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Benjamin Van Tassell, PharmD</name_or_title>
      <organization>Virginia Commonwealth University</organization>
      <phone>8048284583</phone>
      <email>bvantassell@vcu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

